Finally, imatinib induced reduction in tumor growth in xenografts with mutated ABL1 and simultaneous lack of response observed for xenografts with wild‐type ABL1 highlights the therapeutic potential of imatinib in NSCLC patients with ABL1 mutations. This evidence concerns the gene ABL1 and neoplasm.